Biotricity is revolutionizing cardiac care with its cutting-edge remote diagnostic and monitoring solutions that cater to a $35 billion total addressable market opportunity. By integrating advanced hardware and proprietary software, Biotricity has established a new paradigm in cardiac care. The Company’s robust technology platform and product ecosystem, featuring FDA-cleared smart cardiac monitors, coupled with a comprehensive cloud ecosystem, ensure seamless management of patient health across all stages of cardiac care. Utilized daily by cardiologists across 34 states and 500 centers, Biotricity has captured an 8% market share in cardiology, bolstered by a remarkable 99.2% retention rate and an LTV/CAC ratio of 9.

Biotricity reported record margins of 69% in FY2Q24 and expects margins to improve to 80% in the near-term. The Company’s revenue run rate, which was $14 million as of September 30, 2023, is expected to increase to $20 million over the next 12 months as Biotricity’s strategic partnerships with leading Integrated Delivery Networks (IDNs) and Group Purchasing Organizations (GPOs) are set to accelerate growth. Significantly, 93% of the Company’s trailing 12-month revenue is recurring, thanks to its technology-as-a-service model, paving a clear path to profitability with positive EBITDA anticipated in the next six months. Biotricity’s leadership team has over 100 years of collective startup experience and a proven track record of successfully launching 70+ products in over 30 countries. With its strong technological foundation, clear path to profitability, strategic market positioning, and experienced leadership, Biotricity represents a compelling value proposition for investors seeking to capitalize on the rapidly evolving medtech space.

• Robust Technology Platform and Product Ecosystem
  • Smart cardiac monitors and comprehensive cloud ecosystem designed to manage patient health seamlessly across various stages of cardiac care, from diagnostics to chronic disease management
  • Proprietary FDA-approved cardiac monitoring solutions, including the Bioflux and the newly launched Biotres, are utilized daily by cardiologists across 34 states and 500 cardiology centers
  • Holds an 8% market share in cardiology, supported by a 99.2% retention rate and a Lifetime Value to Customer Acquisition Cost (LTV/CAC) ratio of 9
• Strong margins and double-digit revenue growth
  • Record margins of 69% in FY2Q24; margins expected to improve to 80%
  • $14 million run rate as of September 30, 2023; expected to reach $20 million over next 12 months.
  • 93% of revenue is recurring through technology-as-a-service model
  • Clear path to profitability; positive EBITDA expected over next six months
• Positioned for rapid market expansion
  • Partnerships with leading Integrated Delivery Networks (IDNs) and Group Purchasing Organizations (GPOs) anticipated to drive accelerate growth over next 12-18 months
  • Current reach includes 2,500 physicians providing access to six million patients
  • Product ecosystem expansion increased TAM from $1B to $35B in 2023
  • Devices and services are insurance reimbursable, including Medicare, en suring accessibility to patients without out-of-pocket expenses
• Strong leadership
  • 100+ years of collective startup experience
  • Proven record of raising $100M+ capital across multiple companies/ industries
  • Executive team has experience developing 70 products successfully launched in 30+ countries

RedChip Investor Group Call with Biotricity (NASDAQ: BTCY)

Thursday, April 4, 2024

Watch Replay Now